Abstract
Herein, we developed innovative EGFR inhibitor using the FBDD approach. Compound 30a emerged as highly potent, selective, capable of arresting the cell cycle, and inducing apoptosis, underscoring its potential as a novel anticancer therapeutic agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have